Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer

Dose-Response

Volumn 8, Issue 3, 2010, Pages 253-284

  Reynolds, Andrew R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Angiogenesis; Anti angiogenic therapy; Biphasic; Chemotherapy; Hormesis; Pharmacodynamics

Indexed keywords

EID: 78649416421     PISSN: None     EISSN: 15593258     Source Type: Journal    
DOI: 10.2203/dose-response.09-049.Reynolds     Document Type: Article

References (152)

1. Albertsson P, Lennernas B & Norrby K. 2008. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A. Acta Oncol 47:293-300.
2. Albertsson P, Lennernas B & Norrby K. 2009. Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis. Acta Oncol 48:418-425.
3. Aznavoorian S, Stracke ML, Krutzsch H, Schiffmann E & Liotta LA. 1990. Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol 110:1427-438.
4. Baker LH, Rowinsky EK, Mendelson D, Humerickhouse RA, Knight RA, Qian J, Carr RA, Gordon GB & Demetri GD. 2008. Randomized, phase II study of the thrombospondin-1-mimetic angiogen-esis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 26:5583-5588.
5. Bergers G & Hanahan D. 2008. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603.
6. Bertolini F, Shaked Y, Mancuso P & Kerbel RS. 2006. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6:835-845.
7. Blowers E & Hall K. 2009. Managing adverse events in the use of bevacizumab and chemotherapy. Br J Nurs 18:351-6, 358.
8. Boehm T, Folkman J, Browder T & O'Reilly MS. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-7.
9. Bretscher MS. 1996. Moving membrane up to the front of migrating cells. Cell 85:465-7.
10. Brooks PC, Clark RA & Cheresh DA. 1994a. Requirement of vascular integrin alpha v beta 3 for angio-genesis. Science 264:569-71.
11. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G & Cheresh DA. 1994b. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angio-genic blood vessels. Cell 79:1157-64.
12. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH & Cheresh DA. 1995. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815-22.
13. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS & Folkman J. 2000. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-86.
14. Bruns CJ, Koehl GE, Guba M, Yezhelyev M, Steinbauer M, Seeliger H, Schwend A, Hoehn A, Jauch KW & Geissler EK. 2004. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 10:2109-19.
15. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM & Miller KD. 2008. Phase II study of sunitinib malate, an oral mul-titargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-6.
16. Calabrese EJ. 2005. Cancer biology and hormesis: human tumor cell lines commonly display hormet-ic (biphasic) dose responses. Crit Rev Toxicol 35:463-582.
17. Calabrese EJ. 2009. Getting the dose-response wrong: why hormesis became marginalized and the threshold model accepted. Arch Toxicol 83:227-47.
18. Calabrese EJ & Baldwin LA. 2003. Chemotherapeutics and hormesis. Crit Rev Toxicol 33:305-53.
19. Calabrese EJ, Stanek EJ, 3rd, Nascarella MA & Hoffmann GR. 2008. Hormesis predicts low-dose responses better than threshold models. Int J Toxicol 27:369-78.
20. Calabrese EJ, Staudenmayer JW & Stanek EJ. 2006a. Drug development and hormesis: changing conceptual understanding of the dose response creates new challenges and opportunities for more effective drugs. Curr Opin Drug Discov Devel 9:117-23.
21. Calabrese EJ, Staudenmayer JW, Stanek EJ, 3rd & Hoffmann GR. 2006b. Hormesis outperforms threshold model in National Cancer Institute antitumor drug screening database. Toxicol Sci 94:368-78.
22. Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, Dell'Agnola C, Martinelli G, Shultz L & Bertolini F. 2003. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 9:377-82.
23. Carmeliet P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-95.
24. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W & Nagy A. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-9.
25. Casanovas O, Hicklin DJ, Bergers G & Hanahan D. 2005. Drug resistance by evasion of antiangio-genic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309.
26. Caswell P & Norman J. 2008. Endocytic transport of integrins during cell migration and invasion. Trends Cell Biol 18:257-63.
27. Caswell PT, Chan M, Lindsay AJ, McCaffrey MW, Boettiger D & Norman JC. 2008. Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol 183:143-55.
28. Celik I, Surucu O, Dietz C, Heymach JV, Force J, Hoschele I, Becker CM, Folkman J & Kisker O. 2005. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65:11044-50.
29. Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC, Shaw DE, Mazar AP & Cohen RB. 2006. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 94:1621-6.
30. Clamp AR & Jayson GC. 2005. Proteolytic fragments of extracellular matrix components as angio-genic regulators. In: Zubar, RV (ed.) Trends in Angiogenesis Research. Nova Biomedical Publishers, New York.
31. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J & Ferrara N. 2009. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15:21-34.
32. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL & McConkey DJ. 2004. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 10:33-42.
33. De Palma M & Naldini L. 2006. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 1766:159-66.
34. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, Goodman SL & Kessler H. 1999. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 42:3033-40.
35. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Noel A & Foidart JM. 2002. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 16:147-54.
36. Donate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS & Mazar AP. 2008. Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res 14:2137-144.
37. Drixler TA, Borel Rinkes IH, Ritchie ED, van Vroonhoven TJ, Gebbink MF & Voest EE. 2000. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metas-tases after partial hepatectomy. Cancer Res 60:1761-5.
38. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB & Figlin R. 2007. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 13:6689-95.
39. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG & Kerbel RS. 2009a. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-9.
40. Ebos JM, Lee CR & Kerbel RS. 2009b. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15:5020-5.
41. Eder JP, Jr., Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J & Kufe DW. 2002. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20:3772-84.
42. Eikesdal HP & Kalluri R. 2009. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol.
43. Ellis LM & Hicklin DJ. 2008. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-91.
44. Emmenegger U & Kerbel RS. 2007. Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. Onkologie 30:606-8.
45. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A & Moore N. 2007. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103-11.
46. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J & van Oosterom AT. 2003. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39:917-26.
47. Feldman AL, Alexander HR, Jr., Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM & Libutti SK. 2002. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 95:1637-43.
48. Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander HR, Jr. & Libutti SK. 2000. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 6:4628-34.
49. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ & Moore MW. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-42.
50. Ferrara N, Hillan KJ, Gerber HP & Novotny W. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400.
51. Ferrara N & Kerbel RS. 2005. Angiogenesis as a therapeutic target. Nature 438:967-74.
52. Folkman J. 1971. Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-6.
53. Folkman J. 2006. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312:594-607.
54. Folkman J. 2007. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273-86.
55. Fox E, Curt GA & Balis FM. 2002. Clinical trial design for target-based therapy. Oncologist 7:401-9.
56. Friess H, Langrehr JM, Oettle H, Raedle J, Niedergethmann M, Dittrich C, Hossfeld DK, Stoger H, Neyns B, Herzog P, Piedbois P, Dobrowolski F, Scheithauer W, Hawkins R, Katz F, Balcke P, Vermorken J, van Belle S, Davidson N, Esteve AA, Castellano D, Kleeff J, Tempia-Caliera AA, Kovar A & Nippgen J. 2006. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6:285.
57. Fujimoto K, Ichimori Y, Yamaguchi H, Arai K, Futami T, Ozono S, Hirao Y, Kakizoe T, Terada M & Okajima E. 1995. Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn J Cancer Res 86:182-6.
58. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P & ten Dijke P. 2002. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21:1743-53.
59. Hanahan D & Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-64.
60. Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, Baron A, Gallemann D, Colevas D & Eckhardt SG. 2007. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18:1400-7.
61. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT & Abbruzzese JL. 2002. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804-14.
62. Hodivala-Dilke KM, Reynolds AR & Reynolds LE. 2003. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res 314:131-44.
63. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD & Wiegand SJ. 1999. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-8.
64. Hood JD & Cheresh DA. 2002. Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91-100.
65. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD & Motzer RJ. 2009. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a phar-macokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol.
66. Humar R, Kiefer FN, Berns H, Resink TJ & Battegay EJ. 2002. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16:771-80.
67. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R & Kabbinavar F. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-42.
68. Hutson TE, Figlin RA, Kuhn JG & Motzer RJ. 2008. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13:1084-96.
69. Hynes RO. 2002. A reevaluation of integrins as regulators of angiogenesis. Nat Med 8:918-21.
70. Hynes RO, Lively JC, McCarty JH, Taverna D, Francis SE, Hodivala-Dilke K & Xiao Q. 2002. The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb Symp Quant Biol 67:143-53.
71. Jain RK. 2001. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-9.
72. Jain RK. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62.
73. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, 3rd, Gaudreault J, Damico LA, Holmgren E & Kabbinavar F. 2004. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-91.
74. Jones MC, Caswell PT & Norman JC. 2006. Endocytic recycling pathways: emerging regulators of cell migration. Curr Opin Cell Biol 18:549-57.
75. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S & Bergsland E. 2003. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-5.
76. Kamba T & McDonald DM. 2007. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-95.
77. Karagiannis ED & Popel AS. 2007. Anti-angiogenic peptides identified in thrombospondin type I domains. Biochem Biophys Res Commun 359:63-9.
78. Kasper HU, Ebert M, Malfertheiner P, Roessner A, Kirkpatrick CJ & Wolf HK. 2001. Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch 438:116-20.
79. Kerbel R & Folkman J. 2002. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-39.
80. Kerbel RS. 2005. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 8:269-71.
81. Kerbel RS. 2008. Tumor angiogenesis. N Engl J Med 358:2039-49.
82. Kerbel RS & Kamen BA. 2004. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-36.
83. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Donate F, Shaw DE, Mazar AP & Rabbani SA. 2006. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 5:2271-80.
84. Kishi M, Nakamura M, Nishimine M, Ishida E, Shimada K, Kirita T & Konishi N. 2003. Loss of het-erozygosity on chromosome 6q correlates with decreased thrombospondin-2 expression in human salivary gland carcinomas. Cancer Sci 94:530-5.
85. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR & Folkman J. 2001. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61:7669-74.
86. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P & Kerbel RS. 2000. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-24.
87. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D & Kerbel RS. 2002. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8:221-32.
88. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS & Christian MC. 2001. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 19:265-72.
89. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP & Fuchs CS. 2006. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24:3555-61.
90. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK & Cheung M. 2007. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6:2012-21.
91. Lebrin F, Deckers M, Bertolino P & Ten Dijke P. 2005. TGF-beta receptor function in the endotheli-um. Cardiovasc Res 65:599-608.
92. Leenders WP, Kusters B, Verrijp K, Maass C, Wesseling P, Heerschap A, Ruiter D, Ryan A & de Waal R. 2004. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 10:6222-30.
93. Legler DF, Wiedle G, Ross FP & Imhof BA. 2001. Superactivation of integrin alphavbeta3 by low antagonist concentrations. J Cell Sci 114:1545-53.
94. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S & Upadhyaya A. 2000. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 60:309-20.
95. Macluskey M, Baillie R, Morrow H, Schor SL & Schor AM. 2006. Extraction of RNA from archival tissues and measurement of thrombospondin-1 mRNA in normal, dysplastic, and malignant oral tissues. Br J Oral Maxillofac Surg 44:116-23.
96. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD & McDonald DM. 2006. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610-21.
97. Maubant S, Saint-Dizier D, Boutillon M, Perron-Sierra F, Casara PJ, Hickman JA, Tucker GC & Van Obberghen-Schilling E. 2006. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 108:3035-44.
98. Mehta R, Kyshtoobayeva A, Kurosaki T, Small EJ, Kim H, Stroup R, McLaren CE, Li KT & Fruehauf JP. 2001. Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res 7:81-8.
99. Miao WM, Seng WL, Duquette M, Lawler P, Laus C & Lawler J. 2001. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res 61:7830-9.
100. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D & Davidson NE. 2007. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-76.
101. Miquerol L, Langille BL & Nagy A. 2000. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 127:3941-6.
102. Morishita T, Mii Y, Miyauchi Y, Miura S, Honoki K, Aoki M, Kido A, Tamai S, Tsutsumi M & Konishi Y. 1995. Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats. Jpn J Clin Oncol 25:25-31.
103. Motegi K, Harada K, Ohe G, Jones SJ, Ellis IR, Crouch DH, Schor SL & Schor AM. 2008. Differential involvement of TGF-beta1 in mediating the motogenic effects of TSP-1 on endothelial cells, fibroblasts and oral tumour cells. Exp Cell Res 314:2323-33.
104. Motegi K, Harada K, Pazouki S, Baillie R & Schor AM. 2002. Evidence of a bi-phasic effect of throm-bospondin-1 on angiogenesis. Histochem J 34:411-21.
105. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X & Figlin RA. 2009. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-90.
106. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM & Figlin RA. 2007. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-24.
107. Murdoch C, Muthana M, Coffelt SB & Lewis CE. 2008. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8:618-31.
108. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD & Grossman SA. 2007. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651-7.
109. Nascarella MA & Calabrese EJ. 2009. The relationship between the IC(50), toxic threshold, and the magnitude of stimulatory response in biphasic (hormetic) dose-responses. Regul Toxicol Pharmacol 54:229-33.
110. Nisato RE, Tille JC, Jonczyk A, Goodman SL & Pepper MS. 2003. Alphav beta 3 and alphav beta 5 inte-grin antagonists inhibit angiogenesis in vitro. Angiogenesis 6:105-19.
111. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR & Folkman J. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-85.
112. Ohlund D, Ardnor B, Oman M, Naredi P & Sund M. 2008. Expression pattern and circulating levels of endostatin in patients with pancreas cancer. Int J Cancer 122:2805-10.
113. Olsson AK, Dimberg A, Kreuger J & Claesson-Welsh L. 2006. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7:359-71.
114. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL & Weinberg RA. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335-48.
115. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D & Casanovas O. 2009. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-31.
116. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J & Kaipainen A. 2002. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110:923-32.
117. Park M, Lyons J, 3rd, Oh H, Yu Y, Woltering EA, Greenway F & York DA. 2008. Enterostatin inhibition of angiogenesis: possible role of pAMPK and vascular endothelial growth factor A (VEGF-A). Int J Obes (Lond) 32:922-9.
118. Parr C, Watkins G, Boulton M, Cai J & Jiang WG. 2005. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 41:2819-27.
119. Pepper MS, Vassalli JD, Orci L & Montesano R. 1993. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 204:356-63.
120. Perron-Sierra F, Saint Dizier D, Bertrand M, Genton A, Tucker GC & Casara P. 2002. Substituted ben-zocyloheptenes as potent and selective alpha(v) integrin antagonists. Bioorg Med Chem Lett 12:3291-6.
121. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter KC, Harris AL, Fox S, Buyse M, Pilotti S, Pierotti M & Rilke F. 1997. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151:1417-23.
122. Pratt DA, Miller WR & Dawes J. 1989. Thrombospondin in malignant and non-malignant breast tissue. Eur J Cancer Clin Oncol 25:343-50.
123. Rafii S, Lyden D, Benezra R, Hattori K & Heissig B. 2002. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826-35.
124. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R & Harris AL. 1997. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothe-lial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-9.
125. Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, Da Violante G, Gourlaouen M, Salih M, Jones MC, Jones DT, Saunders G, Kostourou V, Perron-Sierra F, Norman JC, Tucker GC & Hodivala-Dilke KM. 2009. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15:392-400.
126. Reynolds AR & Hodivala-Dilke KM. 2009. Will integrin inhibitors have proangiogenic effects in the clinic? Reply. Nat Med 15:727.
127. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF & Shuman MA. 2000. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-14.
128. Ruoslahti E & Pierschbacher MD. 1987. New perspectives in cell adhesion: RGD and integrins. Science 238:491-7.
129. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F & Cassidy J. 2008. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-9.
130. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R & Johnson DH. 2006. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-50.
131. Shojaei F & Ferrara N. 2008. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 11:219-30.
132. Slaton JW, Perrotte P, Inoue K, Dinney CP & Fidler IJ. 1999. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5:2726-34.
133. Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, Clarke J & Harris AL. 1999. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol 10:707-13.
134. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarty MF, Bucana CD, Mazar AP & Ellis LM. 2003. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 104:496-503.
135. Straume O & Akslen LA. 2001. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 159:223-35.
136. Strieth S, Eichhorn ME, Sutter A, Jonczyk A, Berghaus A & Dellian M. 2006. Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. Int J Cancer 119:423-31.
137. Strijbos MH, Gratama JW, Kraan J, Lamers CH, den Bakker MA & Sleijfer S. 2008. Circulating endothelial cells in oncology: pitfalls and promises. Br J Cancer 98:1731-5.
138. Stupp R, Goldbrunner, R., Neyns, B., Schlegel, U., Clement, P., Grabenbauer, G.G., Hegi, M.E., Nippgen, J., Picard, M. & Weller, M.2007. Society for Neuro-Oncology, 12th Annual Meeting, Dallas, TX, USA, November 2007, Abstract No. MA-10.
139. Taraboletti G, Morbidelli L, Donnini S, Parenti A, Granger HJ, Giavazzi R & Ziche M. 2000. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J 14:1674-6.
140. Tjin Tham Sjin RM, Naspinski J, Birsner AE, Li C, Chan R, Lo KM, Gillies S, Zurakowski D, Folkman J, Samulski J & Javaherian K. 2006. Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther 13:619-27.
141. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ & Bouck N. 1993. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122:497-511.
142. Tucker GC. 2003. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 4:722-31.
143. Urbich C, Dernbach E, Zeiher AM & Dimmeler S. 2002. Double-edged role of statins in angiogene-sis signaling. Circ Res 90:737-44.
144. Varner JA & Cheresh DA. 1996. Integrins and cancer. Curr Opin Cell Biol 8:724-30.
145. Veschini L, Belloni D, Foglieni C, Cangi MG, Ferrarini M, Caligaris-Cappio F & Ferrero E. 2007. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 109:2565-70.
146. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jurgensmeier JM & Ogilvie DJ. 2005. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-400.
147. Weis M, Heeschen C, Glassford AJ & Cooke JP. 2002. Statins have biphasic effects on angiogenesis. Circulation 105:739-45.
148. Weis SM, Stupack DG & Cheresh DA. 2009. Agonizing integrin antagonists? Cancer Cell 15:359-61.
149. Weller M, Reardon D, Nabors B & Stupp R. 2009. Will integrin inhibitors have proangiogenic effects in the clinic? Nat Med 15:726; author reply 727.
150. Yao L, Zhao YL, Itoh S, Wada S, Yue L & Furuta I. 2000. Thrombospondin-1 expression in oral squa-mous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival. Oral Oncol 36:539-44.
151. Zhang X, Connolly C, Duquette M, Lawler J & Parangi S. 2007. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Lett 247:143-9.
152. Zhang X & Lawler J. 2007. Thrombospondin-based antiangiogenic therapy. Microvasc Res 74:90-9.